Avalo Therapeutics, Inc.

Equities

AVTX

US05338F3064

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-20 pm EDT			5-day change	1st Jan Change
11.1 ^USD	+15.75%		+2.59%	+21.98%

May. 13	Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 17	North American Morning Briefing : Stock Futures -2-	DJ

Cerecor Inc. Provides Revenue Guidance for the Year 2019

November 14, 2019 at 06:30 am EST

Cerecor Inc. provided revenue guidance for the year 2019. The company is on track to achieve its 2019 revenue guidance in a range of $20 million to $22 million. However, as a result of the sale of the Pediatric Portfolio to Aytu, Cerecor will no longer be providing revenue guidance.

Latest news about Avalo Therapeutics, Inc.

Avalo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 13	CI
North American Morning Briefing : Stock Futures -2-	Apr. 17	DJ
Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35	Apr. 16	MT
Avalo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Sector Update: Health Care Stocks Rise Late Afternoon	Mar. 28	MT
Top Midday Gainers	Mar. 28	MT
Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	Mar. 28	MT
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Thursday Ahead of Key Economic Data	Mar. 28	MT
US Futures Little Changed Pre-Bell Thursday Ahead of Raft of Economic Data	Mar. 28	MT
Top Premarket Gainers	Mar. 28	MT
Avalo Therapeutics, Inc. announced that it has received $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, BVF Partners L.P., RA Capital Management, L.P., Commodore Capital LP, Petrichor Holdings, LLC	Mar. 27	CI
Avalo Therapeutics, Inc. acquired AlmataBio, Inc. for $42.5 million.	Mar. 27	CI
Avalo Therapeutics Shares Triple After Acquisition of AlmataBio, Private Placement Financing of Up to $185 Million	Mar. 27	MT
Avalo Therapeutics, Inc. Announces Board Appointments	Mar. 27	CI
North American Morning Briefing : Stocks Edge -2-	Mar. 27	DJ
Avalo Therapeutics, Inc. announced that it expects to receive $115.6 million in funding from Deep Track Capital, LP, TCG Crossover Management, LLC, Commodore Capital, BVF Partners L.P., Petrichor Energy Inc., RA Capital Management, L.P.	Mar. 26	CI
Avalo Therapeutics Plans 1-for-240 Reverse Stock Split	Dec. 27	MT
North American Morning Briefing : Stock Futures Dip as Inflation Data Looms	Nov. 13	DJ
Avalo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Earnings Flash (AVTX) AVALO THERAPEUTICS Reports Q3 Revenue $236,000	Nov. 09	MT
North American Morning Briefing : Stocks Look to -2-	Nov. 06	DJ
Avalo Therapeutics, Inc. Repays All Outstanding Principal Inclusive of the Final Payment Fee and Interest on the Note in the Aggregate Amount of $14,251,320	23-09-26	CI
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation	23-09-26	CI
Avalo Therapeutics, Inc. announced that it has received $35 million in funding from Horizon Technology Finance Management, LLC	23-09-25	CI
Top Midday Gainers	23-09-12	MT

Chart Avalo Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Avalo Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The Company's lead asset is AVTX-009, an anti-IL-1Î² mAb, targeting inflammatory diseases. Its pipeline also includes quisovalimab (AVTX-002) (anti-LIGHT monoclonal antibody (mAb)) and AVTX-008 (BTLA agonist fusion protein). AVTX-009 is a humanized monoclonal antibody (IgG4) that binds to interleukin-1Î² (IL-1Î²) with high affinity and neutralizes its activity. IL-1Î² is a central driver in the inflammatory process. Quisovalimab shows reduction of Lymphotoxin-like, exhibits Inducible expression, and competes with HSV Glycoprotein D for Herpesvirus Entry Mediator (HVEM), a receptor expressed by T lymphocytes (LIGHT) levels, as well as a favorable safety and tolerability profile, in all indications studied including COVID-19 acute respiratory distress syndrome (ARDS), Crohn's Disease, and non-eosinophilic asthma (NEA).

Sector

Biotechnology & Medical Research

Calendar

2024-07-31 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

11.1 USD

Average target price

35 USD

Spread / Average Target

+215.32%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVALO THERAPEUTICS, INC.	+21.98%	11.48M
MODERNA, INC.	+41.79%	54.04B
IQVIA HOLDINGS INC.	-0.56%	41.92B
LONZA GROUP AG	+47.19%	41.96B
CELLTRION, INC.	-7.20%	28.35B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.35B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	19B
BIO-TECHNE CORPORATION	+6.92%	13B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.19B
MEDPACE HOLDINGS, INC.	+29.60%	12.28B

Other Biotechnology & Medical Research